compound tirzepatide lawsuit Zepbound copycats remain online despite FDA ban US judge denies injunction, restricting

For most patients, this means listing the diabetes diagnosis (E11.XX) as the primary code and the obesity diagnosis (E66.XX) as a secondary code

Portion tools: Use a food scale, then transition to visual cues when logging becomes second nature

Specifically, the company states that FDA-approved GLP-1/GIP medications for weight loss and type 2 diabetes, including Ozempic, Wegovy, Zepbound, and Mounjaro, "may also be eligible for coverage." The company further states that while they "assist with prior authorizations and prescription submissions," they "do not bill insurance directly." This distinction is important: the compounded GLP-1 program itself is described as a cash-pay arrangement, but the company also facilitates access to FDA-approved branded medications that may have insurance pathways

doi: 10.5223/pghn.2014.17.4.203